PolyPid to show D-PLEX₁₀₀ gives 30-day drug release in Phase 3

PolyPid will present new Phase 3 SHIELD II data for its D-PLEX₁₀₀ product at the ESCMID Global 2026 conference, showing the drug's ability to provide a sustained local release of the antibiotic doxycycline for 30 days and potentially reduce surgical site infections.

"This analysis demonstrates D-PLEX₁₀₀'s prolonged delivery mechanism, which is designed to deliver a continuous release of doxycycline for 30 days at the surgical incision site," the company said in a statement.

The presentation will feature an analysis demonstrating the prolonged delivery mechanism of D-PLEX₁₀₀. This technology allows for a steady, local concentration of doxycycline over a 30-day period, a key factor in preventing post-operative infections. The SHIELD II trial is a pivotal Phase 3 study evaluating the efficacy and safety of D-PLEX₁₀₀ in preventing surgical site infections in colorectal surgery.

For PolyPid, a clinical-stage biotech company, positive Phase 3 data is a significant de-risking event that could increase its stock price and validate its core PLEX technology platform. This presentation is a key step towards potential regulatory submissions and future commercialization, which could address a market with a significant unmet need in preventing surgical site infections. The company has not yet disclosed its cash runway.

This article is for informational purposes only and does not constitute investment advice.